Gland Pharma appoints Satnam Singh Loomba as COO

Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.

Gland Pharma receives approval for cetrorelix acetate for injection

Gland Pharma receives USFDA approval for Eribulin Mesylate Injection

The Product is expected to be the first generic approval on the market

Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr

Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023

Gland Pharma receives 2 observations under 483 for Pashamylaram facility

The company is committed to address the observations and will submit its response to US FDA within the stipulated time

Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr

Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023

Gland Pharma posts Q4 FY23 consolidated PAT at Rs. 78.68 Cr

Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023

USFDA inspection: Zydus Lifesciences and Gland Pharma

The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam

Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%

The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility

Briefs: Gland Pharma, Supriya Lifescience, Hindustan Unilever and Eugia Pharma

Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.